Provectus Biopharmaceuticals, Inc. (PVCT)
USD 0.1
(-3.01%)
USD 0.1
(-3.01%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.1 Million USD | 12.73% |
| 2022 | -3.55 Million USD | 45.33% |
| 2021 | -6.5 Million USD | 22.84% |
| 2020 | -8.42 Million USD | -0.57% |
| 2019 | -8.37 Million USD | -2.75% |
| 2018 | -8.15 Million USD | 39.69% |
| 2017 | -13.51 Million USD | 44.66% |
| 2016 | -24.42 Million USD | 0.31% |
| 2015 | -24.5 Million USD | -139.21% |
| 2014 | -10.24 Million USD | 63.02% |
| 2013 | -27.69 Million USD | -120.38% |
| 2012 | -12.56 Million USD | 35.33% |
| 2011 | -19.43 Million USD | -4.76% |
| 2010 | -18.55 Million USD | -50.56% |
| 2009 | -12.32 Million USD | -19.99% |
| 2008 | -10.26 Million USD | -2.64% |
| 2007 | -10 Million USD | -12.8% |
| 2006 | -8.87 Million USD | 24.59% |
| 2005 | -11.76 Million USD | -170.77% |
| 2004 | -4.34 Million USD | -19.62% |
| 2003 | -3.63 Million USD | 49.0% |
| 2002 | -7.12 Million USD | -5378.53% |
| 2001 | -129.99 Thousand USD | -1030.38% |
| 2000 | -11.5 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -846.84 Thousand USD | -68.01% |
| 2024 Q1 | -504.04 Thousand USD | 24.02% |
| 2023 Q4 | -663.41 Thousand USD | 14.49% |
| 2023 Q2 | -835.06 Thousand USD | 4.31% |
| 2023 Q1 | -872.69 Thousand USD | -19.08% |
| 2023 FY | -3.1 Million USD | 12.73% |
| 2023 Q3 | -775.83 Thousand USD | 7.09% |
| 2022 Q1 | -1.03 Million USD | 16.83% |
| 2022 Q4 | -732.85 Thousand USD | 3.61% |
| 2022 Q3 | -760.34 Thousand USD | 29.46% |
| 2022 FY | -3.55 Million USD | 45.33% |
| 2022 Q2 | -1.07 Million USD | -4.61% |
| 2021 Q4 | -1.23 Million USD | -17.83% |
| 2021 Q2 | -1.57 Million USD | 5.41% |
| 2021 FY | -6.5 Million USD | 22.84% |
| 2021 Q3 | -1.05 Million USD | 33.45% |
| 2021 Q1 | -1.66 Million USD | 0.08% |
| 2020 Q1 | -1.82 Million USD | -17.47% |
| 2020 Q2 | -1.61 Million USD | 11.62% |
| 2020 Q4 | -1.67 Million USD | -6.83% |
| 2020 FY | -8.42 Million USD | -0.57% |
| 2020 Q3 | -1.56 Million USD | 3.12% |
| 2019 Q1 | -1.36 Million USD | 37.4% |
| 2019 Q2 | -2.17 Million USD | -58.95% |
| 2019 Q3 | -1.82 Million USD | 16.41% |
| 2019 Q4 | -1.55 Million USD | 14.55% |
| 2019 FY | -8.37 Million USD | -2.75% |
| 2018 Q2 | -1.45 Million USD | 49.78% |
| 2018 FY | -8.15 Million USD | 39.69% |
| 2018 Q4 | -2.18 Million USD | -36.0% |
| 2018 Q1 | -2.89 Million USD | -6.52% |
| 2018 Q3 | -1.6 Million USD | -10.49% |
| 2017 Q3 | -3.11 Million USD | 5.56% |
| 2017 Q4 | -2.72 Million USD | 12.52% |
| 2017 Q1 | -4.38 Million USD | 12.22% |
| 2017 FY | -13.51 Million USD | 44.66% |
| 2017 Q2 | -3.29 Million USD | 24.94% |
| 2016 Q2 | -5.04 Million USD | 40.7% |
| 2016 Q1 | -8.5 Million USD | 11.87% |
| 2016 Q3 | -5.87 Million USD | -16.5% |
| 2016 Q4 | -5 Million USD | 14.9% |
| 2016 FY | -24.42 Million USD | 0.31% |
| 2015 Q3 | -5.78 Million USD | -27.18% |
| 2015 Q1 | -4.52 Million USD | -654.38% |
| 2015 FY | -24.5 Million USD | -139.21% |
| 2015 Q2 | -4.54 Million USD | -0.44% |
| 2015 Q4 | -9.65 Million USD | -66.99% |
| 2014 FY | -10.24 Million USD | 63.02% |
| 2014 Q4 | 816.24 Thousand USD | 121.77% |
| 2014 Q1 | -6.66 Million USD | 59.83% |
| 2014 Q2 | -643.41 Thousand USD | 90.35% |
| 2014 Q3 | -3.74 Million USD | -482.6% |
| 2013 FY | -27.69 Million USD | -120.38% |
| 2013 Q4 | -16.59 Million USD | -264.56% |
| 2013 Q3 | -4.55 Million USD | -91.5% |
| 2013 Q2 | -2.37 Million USD | 42.99% |
| 2013 Q1 | -4.17 Million USD | -117.08% |
| 2012 Q2 | -3.83 Million USD | 14.21% |
| 2012 FY | -12.56 Million USD | 35.33% |
| 2012 Q1 | -4.46 Million USD | -29.42% |
| 2012 Q4 | -1.92 Million USD | 18.15% |
| 2012 Q3 | -2.34 Million USD | 38.76% |
| 2011 Q4 | -3.45 Million USD | 46.42% |
| 2011 Q1 | -5 Million USD | -83.76% |
| 2011 FY | -19.43 Million USD | -4.76% |
| 2011 Q2 | -4.53 Million USD | 9.37% |
| 2011 Q3 | -6.44 Million USD | -42.05% |
| 2010 FY | -18.55 Million USD | -50.56% |
| 2010 Q4 | -2.72 Million USD | 63.39% |
| 2010 Q3 | -7.43 Million USD | -34.73% |
| 2010 Q2 | -5.52 Million USD | -92.52% |
| 2010 Q1 | -2.86 Million USD | 7.89% |
| 2009 Q4 | -3.11 Million USD | -10.39% |
| 2009 FY | -12.32 Million USD | -19.99% |
| 2009 Q1 | -2.38 Million USD | 15.06% |
| 2009 Q2 | -4 Million USD | -68.17% |
| 2009 Q3 | -2.82 Million USD | 29.58% |
| 2008 Q3 | -2.41 Million USD | 10.47% |
| 2008 Q4 | -2.8 Million USD | -16.19% |
| 2008 FY | -10.26 Million USD | -2.64% |
| 2008 Q1 | -2.35 Million USD | 9.24% |
| 2008 Q2 | -2.69 Million USD | -14.43% |
| 2007 FY | -10 Million USD | -12.8% |
| 2007 Q1 | -2.38 Million USD | -14.59% |
| 2007 Q2 | -2.3 Million USD | 3.37% |
| 2007 Q3 | -2.71 Million USD | -17.6% |
| 2007 Q4 | -2.59 Million USD | 4.35% |
| 2006 Q4 | -2.08 Million USD | 3.37% |
| 2006 FY | -8.87 Million USD | 24.59% |
| 2006 Q1 | -2.3 Million USD | 52.61% |
| 2006 Q2 | -2.32 Million USD | -1.27% |
| 2006 Q3 | -2.15 Million USD | 7.41% |
| 2005 Q3 | -2.46 Million USD | 19.92% |
| 2005 FY | -11.76 Million USD | -170.77% |
| 2005 Q4 | -4.85 Million USD | -97.09% |
| 2005 Q1 | -1.37 Million USD | -64.44% |
| 2005 Q2 | -3.07 Million USD | -124.22% |
| 2004 Q1 | -1.15 Million USD | -34.52% |
| 2004 FY | -4.34 Million USD | -19.62% |
| 2004 Q4 | -834.11 Thousand USD | 27.37% |
| 2004 Q3 | -1.14 Million USD | 20.28% |
| 2004 Q2 | -1.44 Million USD | -24.25% |
| 2003 Q1 | -992.68 Thousand USD | 85.81% |
| 2003 FY | -3.63 Million USD | 49.0% |
| 2003 Q3 | -991.25 Thousand USD | -26.09% |
| 2003 Q4 | -861.98 Thousand USD | 13.04% |
| 2003 Q2 | -786.12 Thousand USD | 20.81% |
| 2002 Q1 | -6594.00 USD | 94.34% |
| 2002 Q4 | -6.99 Million USD | -13279.05% |
| 2002 Q3 | -52.29 Thousand USD | -36.94% |
| 2002 Q2 | -38.18 Thousand USD | -479.15% |
| 2002 FY | -7.12 Million USD | -5378.53% |
| 2001 Q1 | -10 Thousand USD | -150.0% |
| 2001 Q3 | -3400.00 USD | 0.0% |
| 2001 Q2 | - USD | 100.0% |
| 2001 FY | -129.99 Thousand USD | -1030.38% |
| 2001 Q4 | -116.59 Thousand USD | -3329.24% |
| 2000 FY | -11.5 Thousand USD | 0.0% |
| 2000 Q2 | - USD | 100.0% |
| 2000 Q1 | -31.5 Thousand USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | 20 Thousand USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -132.267% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 55.58% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 105.855% |
| Nascent Biotech, Inc. | -2.08 Million USD | -48.575% |
| Rebus Holdings, Inc. | -1.02 Million USD | -204.095% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 104.762% |
| Qrons Inc. | -789.34 Thousand USD | -292.954% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -390.47% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 95.045% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -646.552% |
| Skye Bioscience, Inc. | -37.64 Million USD | 91.76% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 95.862% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 52.833% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1034.508% |
| SQZ Biotechnologies Company | -79.46 Million USD | 96.097% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -7.239% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -70.377% |
| Mesoblast Limited | -87.95 Million USD | 96.474% |
| Marizyme, Inc. | -65.34 Million USD | 95.253% |
| Genus plc | 7.9 Million USD | 139.263% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 71.522% |
| Pharming Group N.V. | -10.54 Million USD | 70.594% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -42.951% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 16.4% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 64.928% |
| ContraFect Corporation | -65.15 Million USD | 95.239% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 36.518% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -79.557% |
| IMV Inc. | -36.48 Million USD | 91.499% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 61.515% |
| MultiCell Technologies, Inc. | -380.07 USD | -816004.402% |
| ONE Bio Corp. | 8.67 Million USD | 135.749% |
| Accustem Sciences Inc. | -3.74 Million USD | 17.207% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 94.0% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -144.786% |
| Q BioMed Inc. | -2.05 Million USD | -51.151% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 16.91% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -30.279% |
| Biomind Labs Inc. | -1.21 Million USD | -155.433% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 94.807% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 60.752% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -59.126% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -20611.592% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 80.457% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 46.68% |
| GB Sciences, Inc. | -1.36 Million USD | -127.79% |
| Alpha Cognition Inc. | -13.77 Million USD | 77.479% |
| HST Global, Inc. | -146.21 Thousand USD | -2021.447% |
| CSL Limited | 2.64 Billion USD | 100.117% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -76.762% |
| Halberd Corporation | -79.67 Thousand USD | -3792.977% |
| Enzolytics Inc. | -2.17 Million USD | -42.49% |
| Agentix Corp. | -1.37 Million USD | -125.713% |
| Resverlogix Corp. | -3.61 Million USD | 14.078% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 2.197% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.949% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3265.069% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 144.793% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 21.929% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -2.499% |
| AVAX Technologies, Inc. | -6.41 Million USD | 51.638% |
| Zenith Capital Corp. | -10.59 Million USD | 70.727% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.751% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -13245.53% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 25.185% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -5031.927% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -54.693% |
| Kadimastem Ltd | -3.3 Million USD | 6.217% |
| Helix BioMedix, Inc. | -1.05 Million USD | -193.712% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 18.781% |
| BioStem Technologies, Inc. | -8.48 Million USD | 63.435% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -602.761% |
| LadRx Corporation | 400.44 Thousand USD | 874.584% |
| Cell Source, Inc. | -5.32 Million USD | 41.709% |
| Regen BioPharma, Inc. | 1.02 Million USD | 403.053% |
| Regen BioPharma, Inc. | 1.02 Million USD | 403.053% |
| NovAccess Global Inc. | -4.76 Million USD | 34.962% |
| Affymax, Inc. | -14.42 Million USD | 78.496% |
| Itoco Inc. | -1.86 Million USD | -65.959% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 30.18% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -85.846% |
| Mobile Lads Corp. | -2.26 Million USD | -37.047% |
| CytoDyn Inc. | -49.84 Million USD | 93.777% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -3824.649% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1259.667% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -229.439% |
| SYBLEU INC | -180.3 Thousand USD | -1620.299% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -92.329% |
| International Stem Cell Corporation | -131 Thousand USD | -2267.762% |
| Bioxytran, Inc. | -4.28 Million USD | 27.529% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -5615.227% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -22.588% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 93.548% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -46.725% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -297.211% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 2.091% |
| Neutra Corp. | -233.46 Thousand USD | -1228.579% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 84.714% |
| PureTech Health plc | -65.69 Million USD | 95.279% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 85.415% |
| IXICO plc | -1.17 Million USD | -163.308% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 68.754% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 94.57% |
| CSL Limited | 2.64 Billion USD | 100.117% |
| Cellectis S.A. | -103.17 Million USD | 96.994% |